医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Toshiba Expands Lineup of Photorelays in Industry’s Smallest Package

2014年09月08日 PM05:16
このエントリーをはてなブックマークに追加


 

TOKYO

Toshiba Corporation (TOKYO:6502) today announced that it will expand its lineup of photorelays in the industry’s smallest[1] package with the addition of four products: “TLP3417”, “TLP3420”, “TLP3440” and “TLP3475.” Mass production shipment starts from today. The new products are suited for system solutions in various applications, including semiconductor testers, measurement equipment, probe cards and medical equipment.

Toshiba: Photorelays in Industry's Smallest VSON4 Package (Photo: Business Wire)

Toshiba: Photorelays in Industry’s Smallest VSON4 Package (Photo: Business Wire)

The new products utilize the industry’s smallest package for photocouplers, the Toshiba-developed VSON4[2] package. Compared to equivalent Toshiba products in a USOP4 package, the new photorelays reduce the assembly area by 50% and volume by 60%, which can contribute to enhancing high density assembly.

“TLP3440” has improved leakage characteristics against high frequency at off-state, while “TLP3475” has improved high speed signal transmission characteristics at on-state. Also, for high voltage measurement requirements including SoC testing,“TLP3417” supports 80V, while “TLP3420” supports 100V. The new products have the same electrical characteristics as the conventional Toshiba USOP4 series products; “TLP3317,” “TLP3320,” “TLP3340” and “TLP3375,” making it easier to evaluate them as replacement products.

 

Key Specifications of the New Products

Features   For High Frequency Systems   For High Voltage Systems
Product TLP3440   TLP3475 TLP3417   TLP3420
Package VSON4 Package

Area: 1.5mm × 2.5mm (max.), Height: 1.3mm (max.)

On-state Current 0.12A (max.) 0.3A (max.) 0.12A (max.) 0.08A (max.)
On-state Resistance 12Ω (typ.) 1Ω (typ.) 7.5Ω (typ.) 8Ω (typ.)
Off-state Voltage 40V (min.) 50V (min.) 80V (min.) 100V (min.)
Off-state Capacitance

(Photo Side)

0.45pF (typ.)

12pF (typ.) 5pF (typ.) 6pF (typ.)
Trigger LED Current 3mA (max.)
Isolation Voltage   300Vrms(min.)

Notes:
[1] For photocoupler products, as of September 8, 2014. Toshiba survey.
[2] VSON: Very Small Outline Non-leaded.

Follow this link for more on Toshiba photocouplers and photorelays.
http://www.semicon.toshiba.co.jp/eng/product/opto/coupler/index.html

Customer Inquiries:
Optoelectronic Device Sales & Marketing Department
Tel: +81-3-3457-3431

Information in this document, including product prices and specifications, content of services and contact information, is current on the date of the announcement but is subject to change without prior notice.

About Toshiba

Toshiba Corporation, a Fortune Global 500 company, channels world-class capabilities in advanced electronic and electrical product and systems into five strategic business domains: Energy & Infrastructure, Community Solutions, Healthcare Systems & Services, Electronic Devices & Components, and Lifestyles Products & Services. Guided by the principles of The Basic Commitment of the Toshiba Group, “Committed to People, Committed to the Future”, Toshiba promotes global operations towards securing “Growth Through Creativity and Innovation”, and is contributing to the achievement of a world in which people everywhere live in safe, secure and comfortable society.

Founded in Tokyo in 1875, today’s Toshiba is at the heart of a global network of over 590 consolidated companies employing over 200,000 people worldwide, with annual sales surpassing 6.5 trillion yen (US$63 billion).
To find out more about Toshiba, visit www.toshiba.co.jp/index.htm

Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20140908005376/en/

CONTACT

Media Inquiries:
Toshiba Corporation
Semiconductor & Storage
Products Company
Koji Takahata, +81-3-3457-4963
semicon-NR-mailbox@ml.toshiba.co.jp

同じカテゴリーの記事 

  • ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in HR Positive, HER2 Low Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy in DESTINY-Breast06 Phase 3 Trial
  • PROTEINA Initiates Global Clinical Validation Project with Emory University School of Medicine, USA
  • AriBio 获得欧洲药品管理局对AR1001治疗阿尔茨海默病3期临床试验(POLARIS-AD)的授权
  • AriBio Receives EMA Phase 3 Clinical Trial Authorisation for AR1001 in Treatment of Alzheimer’s Disease (POLARIS-AD)
  • ReNAgadeセラピューティクス、GanNA Bioと糖鎖生物学に対するコミットメントを継続